Alkermes PLC is making strides advancing its proprietary pipeline and expects to file an NDA later this year for what will be its first solely marketed drug since it took commercial control of Vivitrol (naltrexone) in 2008. The most advanced drug in the company’s pipeline is a long-acting injectable (LAI) form of the marketed antipsychotic Abilify (aripiprazole), which could reach the market in 2015 for the treatment of schizophrenia. In preparation, Alkermes is looking to build out its commercial ranks.
Aripiprazole lauroxil would be the first drug Alkermes proactively markets on its own under a new strategy to build a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?